SKIN & AESTHETICS / COMPARE
Two Skin Peptides, Side by Side
Where GLOW and GHK-Cu converge, where they diverge, and — the question this desk keeps returning to — how far the evidence behind each one actually reaches.
The short version
This page lines up the GLOW research blend and GHK-Cu on the dimensions that matter most when reading research peptides: what kind of compound each is, where it has been studied most, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single biggest caution. The headline is this. GHK-Cu, as a standalone, has the most human (mostly topical) evidence of the two — a modest but real controlled human signal. GLOW, as a combination, inherits GHK-Cu's evidence for one constituent but adds two more peptides whose human data are thin, and the blend itself has never been tested as a unit in any controlled study. Neither is an approved medicine, and neither is presented here with a human dose.
The comparison matrix
| Dimension | GLOW (research blend) | GHK-Cu |
|---|---|---|
| Peptide class | Non-standardized combination of three research peptides (GHK-Cu + BPC-157 + TB-500); no single drug class | Copper-binding tripeptide / copper tripeptide-1 (3 aa) |
| Most-studied in | Individual constituents studied in skin matrix (GHK-Cu), angiogenesis and connective tissue (BPC-157), wound re-epithelialization (TB-500); blend untested | Skin regeneration and matrix synthesis; hair; wound healing |
| Evidence base (model) | Single-constituent animal and limited human data; no controlled blend trials [1][2] | In vitro + small human topical trials + one 45-patient combination hair RCT [8][10] |
| Administration studied | Constituents: topical, subcutaneous, IM; co-formulated blend PK unstudied [1] | Topical; ex vivo skin penetration [8][11] |
| Regulatory / WADA status | Not approved as a combination; BPC-157 FDA-flagged for non-compounding; BPC-157 and TB-500 WADA-prohibited | Cosmetic ingredient (topical); systemic unapproved; not on WADA list (verify S0) |
| Key caution | No blend-level trial data; two of three constituents WADA-prohibited; combination PK unknown [1] | Poor skin permeability; localized hyperpigmentation risk; topical-only human evidence [8] |
Peptide class
GHK-Cu is a precisely defined molecule: glycyl-L-histidyl-L-lysine chelated one-to-one to a copper(II) ion, with its sequence occurring naturally inside type I collagen [4]. GLOW is not a molecule at all — it is a supplier- or clinic-formulated combination of three peptides with varying ratios and no standardization. The two compounds differ not just in chemistry but in their epistemic status: a single known molecule has a cleaner evidence base than a combination product that has never been tested as a unit [1].
Most-studied in
GHK-Cu's research home is skin and matrix biology: collagen, elastin, glycosaminoglycans, and the dermal fibroblast response that underpins them [4][5]. GLOW's territory, as represented by its constituents, is broader: GHK-Cu covers the matrix side, BPC-157 covers angiogenesis and connective-tissue repair [3], and TB-500 covers cell migration and re-epithelialization in wound models [7]. Breadth, though, is not the same as depth — and in GLOW's case, no single study has confirmed the constituent evidence translates to the blend [1].
Evidence base (model)
GHK-Cu has the more established evidentiary footing. Small human topical trials, a 2025 review of delivery strategies and clinical outcomes [8], and a controlled 45-patient hair-loss trial [10] provide a thin but real human signal. GLOW's evidence is a different kind of picture: it consists of the sum of its parts. BPC-157's human record is three small pilot studies [2]; TB-500 (as the full-length parent, thymosin beta-4) has a Phase 1 safety study in 40 volunteers but none for the fragment [1]; and the combination itself has no trial data. The 2026 Sports Medicine review that names all three constituents concludes that rigorous human safety data are scarce and the potential for serious harm exists [1].
Administration studied
GHK-Cu is primarily a topical story — creams, serums, microneedle-assisted delivery — with the key quantified finding being how much copper actually crosses the skin [11]. Injectable or systemic GHK-Cu is unapproved and pharmacokinetically uncharacterized in humans [8]. GLOW constituents have been studied by various routes (topical, subcutaneous, intramuscular for BPC-157; intravenous for full-length thymosin beta-4), but the co-formulated blend as given by research communities has no published pharmacokinetic characterization — three peptides with different half-lives, mixed into a single injection, with unknown interaction effects [1].
Regulatory / WADA status
GHK-Cu as a topical ingredient (Copper Tripeptide-1) is a legal cosmetic ingredient in the US and EU; systemic use is unapproved and research-only [8]. GHK-Cu is not on the WADA Prohibited List by name, though WADA's catch-all S0 category can cover non-approved pharmacological substances — verify the current list before any athletic context. For GLOW, the regulatory profile is set by the strictest of its three constituents: BPC-157 has been flagged by the FDA as not eligible for pharmacy compounding pending evaluation, and both BPC-157 and TB-500 are WADA-prohibited at all times [1][2]. Using the blend puts an athlete in violation regardless of the reason.
Key caution
Each compound carries a defining caveat. For GHK-Cu as a standalone, it is that the peptide crosses intact skin poorly without delivery aids, capping the real-world benefit of topical formulations [8], and that injectable evidence in humans is essentially absent [10]. For GLOW, it is that the combination has never been tested as a unit — every claim is borrowed from single-constituent research, often preclinical — and two of its three peptides bring explicit WADA-prohibited and FDA-flagged regulatory exposure [1][2]. Read together, the lesson is consistent: a coherent mechanistic rationale does not substitute for a controlled trial of the actual compound being described.